• Home
  • UCSF at #AACR21

UCSF at #AACR21

AACR banner

Despite the virtual format due to the coronavirus pandemic, UCSF once again had an impressive presence at this year's annual meeting of the AACR. The program has been separated into two parts, Week 1: April 10-15; Week 2: May 17-21, with the theme, “Discovery Science Driving Clinical Breakthroughs.” 

Dozens of the HDFCCC’s 400+ members were represented in abstracts accepted for presentation, and AACR provided investigators of all levels a chance to present and review research, confer with colleagues, and return with new ideas. The highlights from Week 1 are noted below in a list of abstracts, poster presentations, and activity on social media.

>Download the listof UCSF #AACR21 Week 1 presentations

Week 1: April 10-15; Week 2: May 17-21

Featured Presentations

KRAS & RAS

  • Frank McCormick: Progress in targeting KRAS directly 
  • Kevan Shokat: Multimodal direct targeting of K-Ras (G12C) 
  • Alejandro Sweet-Cordero: A novel protein therapeutic that effectively inhibits KRAS mutant lung cancer
  • Pau Castel: Oncoprotein duality in cancer and developmental syndromes: Lessons learned from RAS GTPases

Radiation  

  • Jean Nakamura: Radiation-induced carcinogenesis: Insights from experimental and epidemiologic investigations

Biostatistics

  • Mi-Ok Kim: The problems with P-values are not just with P-values: Proper inference requires full reporting and transparency

Towards Engineering of Neoantigen-Specific T-Cell Therapies:

  • Kole Roybal: Engineering next-generation cell therapeutics with synthetic biology

Cell-Surface Receptors in Immuno-Oncology

  • Jim Wells: Remodeling of the cell surface proteome in cancer

Novel Mechanisms

  • Manasi K Mayekar: APOBEC3B fuels evolution of resistance during targeted cancer therapy

Mechanisms and Biomarkers of Response and Resistance to Immune Therapy

  • Max Krummel: Spatiotemporal definitions of immune archetypes across cancer types

Overcoming Resistance in the Tumor Microenvironment: Novel Immunomodulatory Agents

  • Kira Morgan Downey: Engineering tertiary lymphoid structures for glioblastoma: A novel gene combination promotes therapeutic TLS formation in an immune-competent mouse model of GBM

Advances in Sarcoma Therapy

  • Alejandro Sweet-Cordero: Paracrine Signaling in Cancer    

Integrative Data Analysis and Systems Modeling

  • Wei Wu: Deep learning-based integration of esophageal cancer morphology with genomics

 

Featured Poster Presentations

 

  • Immune Cells in the Tumor Microenvironment
    • Elizabeth Yu: Deciphering macrophage function in lung tumor microenvironment and disease progression
  • Large-Scale Approaches to Cancer Gene Discovery
    • Minkyu Kim: The protein interaction landscape of breast cancer
  • New Algorithms
    • Michael Sharpnack: Exhaustive tumor specific antigen detection with RNAseq
  • Tumor Suppressor Genes
    • Yuichiro Tanaka: Functional properties and regulation of the catechol-O-methyltransferase gene in prostate cancer
    • Ramin Farhad: Functional characterization of chromosomal deletions in head and neck squamous cell carcinoma
  • Supportive Care and Survivorship Research
    • Sam Washington: Longitudinal analysis of the indirect burden of prostate cancer management on paid and unpaid work: Data from CaPSURE database
  • Liquid Biopsies: Circulating DNA
    • Jocelyn Chapman: Circulating tumor DNA predicts disease recurrence in ovarian cancer patients
  • Novel Mechanisms
    • Manasi K. Mayekar: APOBEC3B fuels evolution of resistance during targeted cancer therapy
  • Therapeutic Antibodies, Including Engineered Antibodies
    • Chi-Heng Wu: A CD70 antibody-drug conjugate is highly active and induces long term remission in patient-derived xenograft mouse models of cutaneous T cell lymphoma

Honors

AACR 21 Fellows
Castel AACR21

Twitter Traffic Remained High

#AACR21 Statistics Courtesy of Symplur

Twitter remained an active channel for conversation and promotion of events, with the the modified virtual program offering many abstracts and posters available on demand. We have included some highlights below.